Building a Scalable, Evidence-Aligned Platform for Late-Stage and End-Stage Care
The Mission
We are building an integrated healthcare ecosystem designed for patients facing late-stage and end-stage conditions—particularly where guideline-directed options have been exhausted, where patients are excluded or ineligible for additional standard interventions, or where care priorities shift toward structured supportive and quality-of-life pathways.
Our approach is explicitly not a replacement for modern medicine.
We operate as adjunctive and late-line, governed by documentation, consent, monitoring, and escalation back to standard-of-care whenever needed.
The Opportunity
SGP and Novadigm addresses one of the world’s largest unmet needs: scalable management of complex and end-stage diseases converting deep clinical expertise into a device-enabled, protocolized, and trainable system powered by Docture Poly + PRISM. The addressable market exceeds $1.2 trillion globally and continues to grow with aging populations and chronic disease prevalence.
Why This Matters
From Month 6 after operations begin:
Across chronic and complex diseases—advanced cancers, heart failure, liver failure, kidney failure, autoimmune disorders, and severe refractory metabolic disease—patients and families frequently reach a stage where:
- the marginal benefit of additional guideline steps diminishes,
- eligibility for interventions narrows, and
- care becomes fragmented, expensive, and emotionally exhausting.
This creates an urgent need for structured, responsible, and trackable supportive pathways—especially for end-stage patients.
What We Have Done So Far
Over the past decade, the founder and clinical team report a real-world care footprint that includes:
- 28,000+ end-stage patients supported across 12 clinical categories
- service reach spanning multiple geographies across five continents
- an internally tracked subset of patients who adhered to the protocol showing:
- significant improvement in functional outcomes and quality-of-life measures, and
- in a subset, medication de-escalation under clinical supervision.
Important: These outcomes are observational and internally tracked. We do not claim cures. Our next phase prioritizes prospective registries, monitored cohorts, and publishable evidence generation.
Why It Scales
This architecture enables non-linear revenue growth, smooth EPS expansion, and valuation multiple uplift and allows expert-level care to be delivered consistently across geographies.
The Scientific Foundation
This ecosystem is built on translational research—from experimental models to bedside protocols—supported by:
The goal is a clinically disciplined system that remains in continuity with evidence-based medicine, not in opposition to it.
Seven Verticals Working as One Ecosystem
We are building an ecosystem that monetizes through multiple reinforcing engines:
Polyclinics (Access + Continuity)
Capex-light clinics that drive standardized consult, follow-up, and monitoring.
These clinics are the primary “access layer” for scale.
Nodal Polyclinics (Stabilization Layer)
Regional 20-bed + ICU/IIRCU-style centers designed for supervised stabilization and short-stay care for patients needing closer monitoring.
Hub Hospitals (Governance + Complex Care + Evidence)
Hospitals serve as the clinical anchor for governance, escalation, training, and evidence generation.
Device Platform (Docture- Poly)
A standardized physiological capture and decision-support pathway designed to reduce clinician-to-clinician variability and support scalable implementation.
Premium Wearable Ring (Wellness Membership Layer)
A premium wellness product with continuous monitoring and subscription potential.
Supplements Distribution (Compliant, Quality-Controlled)
Evidence-aligned supplements as adjuncts, distributed through compliant channels with quality assurance and monitoring.
Education + Partnerships (iPRISM)
Clinician training and certification to replicate capability at scale; plus technology and institutional partnerships to accelerate evidence and adoption.
Progress to Date
Scientific & Technology Foundation
Docture Poly Platform
Where We Are Now
How the Engine Works
The SGP × Novadigm engine is designed to scale clinical excellence without depending on individual experts:How the Engine Works
Polyclinics → Nodal Poly clinics → hub hospitals → device subscriptions create layered, reinforcing revenue streams
Why Docture Poly Is the Multiplier (Key Investor Insight)
Without Docture Poly:
With Docture Poly:
Investors stop valuing the company as “₹ per bed” and start valuing it as “₹ per patient under management.”